Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
eventually compete with market-leading medicines from Novo Nordisk and Eli Lilly. In its first official announcement, the biotech, whose existence was revealed by Endpoints News earlier this month, said it has two therapies in clinical testing already. Another “handful” could join in the next year, CEO Clive Meanwell said in an interview. The biotech has raised $290 million in funding, led by co-founding investment firms Arch Venture Partners and Population Health Partners. It's already used some of that cash to build a drug portfolio of oral and injectable drugs as well as prospects that simultaneously target multiple gut hormones. Dive Insight: Like many others in the industry, Meanwell was struck by the success of Lilly's Mounjaro and Novo's Wegovy , which proved so effective in testing that their makers have struggled to keep up with demand Analysts now project a market worth more than $100 billion, a prize that's sparked a gold rush among large and small companies to fo
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Amgen investors await weight-loss drug data [Yahoo! Finance]Yahoo! Finance
- Amgen investors await weight-loss drug data [Reuters]Reuters
- The Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy [Yahoo! Finance Canada]Yahoo! Finance Canada
- Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes [Reuters]Reuters
- Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 5/1/24 - Form 6-K
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website